SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?


To: rkrw who wrote (469)2/18/2010 12:01:22 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 566
 
>> Deal has fairly similar terms as the incy/lly RA deal <<

Yeah, but the deal includes oncology (B/T lymphomas). Thus, apples-to-apples is a comparison to INCY/Lilly AND Novartis.

(Yes, I'm talking two molecules versus one, but development costs through tox aren't particularly noteworthy, once a molecule has reached deep into phase II for an indication that requires large trials.)